Skip to main content

Jaume Alijotas Reig

Institutions of which they are part

Head of group
Systemic Diseases
Vall Hebron Institut de Recerca

Jaume Alijotas Reig

Institutions of which they are part

Head of group
Systemic Diseases
Vall Hebron Institut de Recerca

Research lines

Immunologic lesional mechanisms in late adverse reactions against bioimplants.

The late clinical manifestations that arise when bioimplants are applied seem to have an immunologic basis. We are studying both the histological characteristics and the lesional mechanisms of the most frequently used implants. We try to analyze the role that bacteria may have in the induction and/or maintenance of these reactions and the possible correlation between particular HLA haplotypes and the adverse effects.

IP: Jaume Alijotas Reig

Development of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS/EUROMAP).

The so-called obstetric antiphospholipid syndrome seems to have pathogenic, biologic, therapeutic, and evolution features somehow different from the ones observed in those patients who suffer from "classic" antiphospholipid syndrome. Although experience and scientific evidence seem to support this idea, there is a lack of information that allows us to suggest changes in the classification and/or therapeutic criteria. The European Forum on Antiphospholipid Antibody Syndrome has decided to carry on this project and it has chosen the Vall d'Hebron Hospital as the European Coordinating Centre. Many important Spanish and European hospitals will participate in this multicentric study.

IP: Jaume Alijotas Reig

Immunological alterations as basis of inmunosenescencein pathological aging.

This research line is centered into the study of the role of cross-reactivity among oxidized lipoproteins (oxLDL), antiB2-GP1 and membrane phospholipids, as well as between these complexes and heat shock proteins. We also focus into the role of proinflamatory (IL2 / IL6 / TNFalpha) and anti-inflamatory (IL4 / IL-10) cytokines, as well as with the different activation profiles of TCR and/or CD14 (TLR4) and the role of hormones such as melatonin and the growth hormone.

IP: Jaume Alijotas Reig

Predictive kit to detect the possible establishment of late adverse effects related to bioimplants used in clinical practice.

A high variability in the prevalence of adverse effects with an immunologic basis seems to be related with any implant used in clinical practice. We have managed to find a particular association of HLA haplotypes that increase the risk for developing these effects up to 600 times. We are nowadays working on setting up a safe and reliable biochip or kit which predicts this risk easily in a routine test.

IP: Jaume Alijotas Reig

Projects

Anticuerpos antifosfolipídicos inductores de memoria inmune innata en monocitos como causa de morbilidad obstétrica en el síndrome antifosfolipídico.

IP: Francesc Miro Mur
Collaborators: Jaume Alijotas Reig, José Pardos Gea, Ariadna Anunciacion Llunell
Funding agency: Instituto de Salud Carlos III
Funding: 102500
Reference: PI24/01302
Duration: 01/01/2025 - 31/12/2027

Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing daily Administration as a Treatment Strategy (STATIN-PRE trial)

IP: Jaume Alijotas Reig
Collaborators: Manel Mendoza Cobaleda, Francesc Miro Mur, Enrique Esteve Valverde, Ariadna Anunciacion Llunell
Funding agency: Fundació La Marató de TV3
Funding: 50625
Reference: 202418-33
Duration: 20/09/2025 - 19/09/2028

Ajuts Grups de Recerca (SGR) 2022

IP: Jaume Alijotas Reig
Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Ariadna Anunciacion Llunell
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00048
Duration: 01/01/2022 - 30/06/2025

Be Sure genetic test to determine dermal filler implant adverse reactions

IP: Jaume Alijotas Reig
Collaborators: -
Funding agency: CERCA (Centres de Recerca de Catalunya)
Funding: 10000
Reference: 2020-07-010
Duration: 01/01/2019 - 31/12/2020

Related news

A Vall d’Hebron team demonstrates, for the first time, the potential of optical genome mapping to detect genetic alterations associated with this rare disease that are not identified using conventional methods.

The study describes the first documented case worldwide of hereditary angioedema transmission through assisted reproduction.

15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.

Related professionals

Jose Santos Santiago

Jose Santos Santiago

Senior researcher
Infectious Diseases
Read more
Maria Roch Santed

Maria Roch Santed

Predoctoral researcher
Basic, Translational and Clinical Pharmacy Research
Read more
Inma Salomón Castaño

Inma Salomón Castaño

Research assistant
Cardiovascular Diseases
Read more
Aitana Diaz Vazquez

Aitana Diaz Vazquez

Research technician
Clinical and Translational Bioinformatics
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.